Research programme: small molecule therapeutics - Merck Serono/SGX PharmaceuticalsAlternative Names: Small molecule therapeutics - Merck Serono/Structural GenomiX
Latest Information Update: 06 Oct 2010
At a glance
- Originator Merck Serono; SGX Pharmaceuticals
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 06 Oct 2010 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 08 Jan 2007 Serono is now called Merck Serono
- 05 Jan 2007 Serono has been acquired by Merck KGaA